Kpc Pharmaceuticals, Inc. announced that the company plans to use its own or self-raised funds to acquire 51% of the equity of Kunming Huaren Shenghuo Pharmaceutical Co., Ltd., held by its affiliate China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., for RMB 1.791 billion. After the completion of this equity transfer, Kpc Pharmaceuticals, Inc. will hold a 51% equity interest in China Resources Sanjiu, and China Resources Sanjiu will no longer hold equity in Huaren Shenghuo. This transaction does not constitute a major asset restructuring, does not involve related party transactions, and will not result in a change in the company's control.
昆药集团：拟以17.91亿元收购华润圣火51%股权
Kpc Pharmaceuticals, Inc. intends to purchase a 51% equity transfer of China Resources Sanjiu Medical & Pharmaceutical's Huaren Shenghuo for RMB 1.791 billion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.